isogenica

Isogenica expands collaboration with Aro Biotherapeutics

Under the expanded agreement, Isogenica will use its CIS Display platform to help Aro achieve its goal of developing novel CentyrinsTM against multiple targets for cell - specific delivery.

Dr Adam Collier, Isogenica's Director of Business Development commented: "it is very satisfying to see that the success of the first six months of this collaboration has resulted in this strengthening of the relationship. We look forward to continuing to work with the team at Aro in the search for novel Centyrins TM with high therapeutic potential in onology and immunology".

Read the press release

37th Annual J.P. Morgan HEALTHCARE CONFERENCE

January 7 - 10, 2019 Westin St. Francis Hotel | San Francisco, California

Emma Sceats amd Adam Collier will be in San Fransico for JP Morgan's 37th Annual Healthcare Conference from 6th-10th January 2019 and welcome the opportunity to meet there.

 $\label{eq:bd@isogenica.com} \textit{Email} \ \underline{\textit{bd@isogenica.com}} \ \textit{to connect}.$

BIO-EUROPE SPRING°

MARCH 25 - 27 2019 VIENNA, AUSTRIA

Isogenica will be attending Bio-Europe. This will be an exciting opportunity for us to talk to potential partners. Emma Sceats has also been invitated to attend Leading Biotech's Europe CEO meeting, taking place on 24th March and looks forward to meeting other biotech CEOs and executive leaders also attending.

Speed and success through our focus on synthetic antibodies.

Isogenica is developing LlamdA™ (single domain VHH) and Alexandria™ (human Fab) therapeutic antibodies based on our proprietary fully synthetic antibody libraries and leveraging our CIS Display and Colibra™ technologies to accelerate the discovery







Copyright © 2019 Isogenica, All rights reserved.

Your data is important to us. View our privacy policy here

Our mailing address is: info@isogenica.com

Want to change how you receive these emails?
You can <u>unsubscribe from this list</u>.